Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Eisai’s Halaven Extends OS in Metastatic Breast Cancer Patients
June 4, 2014
- Taiho’s TS-1 Able to Prolong Life for Metastatic, Relapsed Breast Cancer Patients
June 4, 2014
- Shionogi Establishes Wholly Owned Subsidiary in Singapore as Foothold for Development and Marketing in ASEAN States
June 4, 2014
- Nexavar Fails to Show Efficacy in Adjuvant Therapy for Liver Cancer: Bayer Yakuhin
June 4, 2014
- Eisai’s Anticancer Agent Lenvatinib Significantly Extends PFS in PIII Study
June 3, 2014
- Teijin Ups FY2015 Japan Sales Target for Feburic to 20-Plus Billion Yen
June 3, 2014
- MTPC to Merge Its Subsidiary Benesis in October
June 3, 2014
- Astellas Seeks Approval of Cell-Culture Seasonal Flu Vaccine
June 2, 2014
- FDA Approves Eisai’s Aloxi for Pediatric Indication, Grants Additional Six-Month Exclusivity
June 2, 2014
- Announcement: 1st Annual Real World Data Japan 2014 - Tokyo Marriott Hotel, July 15-16
June 2, 2014
- Suglat Secures Top Position in Anterio’s “Mind Share” Ranking in Both GP, HP Markets in April
June 2, 2014
- Astellas, MSD Report 133 ADRs at EPPV for Suglat between January and April
June 2, 2014
- Takeda, US Biotech Venture Agree to Develop, Commercialize Autoimmune Disease Treatment
May 30, 2014
- Europe Approves Takeda’s UC, CD Treatment Entyvio
May 30, 2014
- Daiichi Sankyo to Tout Quick Cardiac Event Reduction for Efient
May 30, 2014
- Bayer Seeks New VTE Indication for Xarelto in Japan
May 30, 2014
- Atypical Antipsychotic Drug Asenapine Significantly Improves Symptoms of Schizophrenia in PIII Trial; Meiji Seika Pharma
May 30, 2014
- Introduction of Joint Bidding System to Result in 100% Price Agreement Rate by September: Mr Takada of Qol
May 30, 2014
- Eisai Receives Positive Opinion from CHMP on Expanded Indication for Halaven for Second-Line Treatment of Advanced Breast Cancer
May 30, 2014
- Shire Japan to Independently Launch Orphan Drug around September
May 29, 2014
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…